EPAS1 and nonpapillary renal cell carcinoma: Based on the critical role of HIF-2a in the carcinogenesis of ccRCC, multiple trials are investigating HIF-2α inhibitors as monotherapy or in combination with immunotherapy or TKIs (Table 3).